Skip to main content

Table 2 Assessment of risk of bias of studies included in the meta-analysis

From: Safety and effectiveness of antimalarial therapy in sickle cell disease: a systematic review and network meta-analysis

Author details Study site Drug regimen Allocation sequence Allocation concealment Blinding No evidence of incomplete outcome data recording No evidence of selective outcome recording
Olaosebikan et al., 2015 Kwara state, Nigeria MQAS
SPAQ
PG
Yes Yes (Open-label)
Laboratory staff were unaware of treatment allocation
MQAS (2 withdrew consent, 3 moved away, 12 lost and 4 deaths)
SPAQ (1 withdrew consent, 2 moved away and 12 lost)
PG (1 moved away, 26 lost and 3 deaths)
Yes b
Diop et al., 2010 Dakar, Senegal PL
SP
Yes Yes Open-label Yesa Yes b
Nakibuuka et al., 2009 Kampala, Uganda SP
CQ
Yes Yes Double-blind SP (7 lost to follow up)
CQ (8 lost to follow up)
Yes b
Eke et al., 2003 Port Harcourt, Nigeria PL
PM
PG
Yes Yes Open-label Yesa Yes b
Nwokolo et al., 2001 Multicenter, Nigeria PG
MQ
Yes Yes Open-label Yesa Yes b
Warley et al., 1965 Kampala, Uganda PL
CQ + benzathine penicillin
Yes Yes Not provided Yesa No (dactylitis and Haemoglobin)
  1. CQ = Chloroquine, MQ = Mefloquine, MQAS = Mefloquine-artesunate, PL = Placebo, PG = Proguanil, SP=Sulfadoxine-pyrimethamine, SPAQ = Sulfadoxine pyrimethamine-amodiaquine
  2. aYes indicates that there is no evidence of incomplete outcome data recording
  3. b Yes indicates that there is no evidence of selective outcome recording